Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Martelli

Showing results (431-440 of 549) with videos related to

Pageof 55
Sort By:
Leukemia|October 29, 2011
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatmentM Y Follo, D Russo, C Finelli, et al.
Advances in Biological Regulation|October 13, 2012
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDSMatilde Y Follo, Sandra Marmiroli, Irene Faenza, et al.
Leukemia|July 30, 2013
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potentialL M Neri, A Cani, A M Martelli, et al.
Cells|April 3, 2020
Lamin A and Prelamin A Counteract Migration of Osteosarcoma CellsCamilla Evangelisti, Francesca Paganelli, Gaia Giuntini, et al.
Sub-Cellular Biochemistry|March 1, 2012
Nuclear phosphoinositides: location, regulation and functionRoberta Fiume, Willem Jan Keune, Irene Faenza, et al.
Advances in Biological Regulation|August 11, 2015
Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cellsTimothy L Fitzgerald, Kvin Lertpiriyapong, Lucio Cocco, et al.
Oncotarget|August 6, 2016
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemiaAyman A M Alameen, Carolina Simioni, Alberto M Martelli, et al.
Oncotarget|January 20, 2018
Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expressionLinda S Steelman, Steve L Abrams, Peter Ruvolo, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 12, 2024
Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal MesotheliomaAnna Caliò, Stefano Marletta, Lavinia Stefanizzi, et al.
Pageof 55

Showing results (431-440 of 549) with videos related to

Sort By:
Pageof 55
Leukemia|October 29, 2011
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatmentM Y Follo, D Russo, C Finelli, et al.
Advances in Biological Regulation|October 13, 2012
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDSMatilde Y Follo, Sandra Marmiroli, Irene Faenza, et al.
Leukemia|July 30, 2013
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potentialL M Neri, A Cani, A M Martelli, et al.
Cells|April 3, 2020
Lamin A and Prelamin A Counteract Migration of Osteosarcoma CellsCamilla Evangelisti, Francesca Paganelli, Gaia Giuntini, et al.
Sub-Cellular Biochemistry|March 1, 2012
Nuclear phosphoinositides: location, regulation and functionRoberta Fiume, Willem Jan Keune, Irene Faenza, et al.
Advances in Biological Regulation|August 11, 2015
Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cellsTimothy L Fitzgerald, Kvin Lertpiriyapong, Lucio Cocco, et al.
Oncotarget|August 6, 2016
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemiaAyman A M Alameen, Carolina Simioni, Alberto M Martelli, et al.
Oncotarget|January 20, 2018
Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expressionLinda S Steelman, Steve L Abrams, Peter Ruvolo, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 12, 2024
Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal MesotheliomaAnna Caliò, Stefano Marletta, Lavinia Stefanizzi, et al.
Pageof 55